Novo Nordisk's 2020 purchase of Corvidia brought ziltivekimab, which later failed a heart trial
A failed heart drug trial shows how Novo Nordisk's pipeline bets sit apart from the semaglutide medicines many US patients know, and what it does and does not mean for approved GLP-1 drugs.
Novo Nordisk agreed on June 11, 2020, to buy Corvidia Therapeutics, a company spun off from AstraZeneca, for $725 million upfront and up to $2.1 billion if milestone payments are reached [1]. The purchase gave Novo an experimental antibody called ziltivekimab, which targets interleukin-6 [1]. About six years later, the drug failed its main cardiovascular outcomes trial [1].
Novo has not reported how many patients were enrolled in that trial, how long they were followed, or how the results differed between groups. The company also has not disclosed what the failure means for the future of ziltivekimab, or whether any of the milestone payments tied to the 2020 agreement were ever triggered. Only the $725 million upfront payment is known to have been committed at signing [1].
Ziltivekimab is not a GLP-1 medicine. It is an anti-interleukin-6 antibody, a different class of drug from the semaglutide products Novo sells as Ozempic, Wegovy and Rybelsus [1]. Novo's business is built mainly on diabetes and obesity medicines and devices, and it markets products in 168 countries [1]. Company figures for 2025 list revenue of 309.1 billion Danish kroner, net income of 102.4 billion kroner and 68,794 employees [1]. Novo Holdings A/S holds about 28.1% of the shares and 77.1% of the voting power [1], and the company's market value passed the size of Denmark's economy in 2023 [1].
The Corvidia purchase was a bet on a drug that works through a different mechanism than Novo's best-selling GLP-1 products, and it shows how far the company was willing to reach outside its main franchise. Most experimental drugs fail at some stage of testing, and Novo has not said how the ziltivekimab program fits into its research spending now.
Why it matters for patients
The failure does not change any medicine that has already been approved. Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) went through their own testing, and ziltivekimab is not an ingredient in any of them [1]. Nothing in the company's disclosures ties this result to the supply, labeling or insurance coverage of those drugs.
For patients with heart disease, the outcome means an experimental option studied for that use is not moving forward on this timeline. Novo has not said whether it will run another trial or pursue a different use for ziltivekimab.
The episode also shows where a large drugmaker's money goes. Novo earns most of its revenue from diabetes and obesity care [1], so a failed heart drug is a setback in one part of the pipeline rather than a change to the products patients already take.
What happens next
Novo Nordisk announced the Corvidia deal on June 11, 2020 [1]. The cardiovascular outcomes trial readout followed about six years later [1]. The company has not said whether it will publish the full trial results, whether it will take a financial charge tied to the purchase, or what it plans to do with ziltivekimab. No dates for those decisions have been reported.
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.